Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
AssigneePrecision Biologics, Inc.
InventorsJ. Andrew BRISTOL, Judith A. KANTOR
Life of this patent
Estimating the term…
Abstract
The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.
Claims21
1-22. (canceled)
An isolated monoclonal antibody, antigen-binding fragment, or derivative thereof, that binds to a human colorectal and pancreatic carcinoma-associated antigen (CPAA), wherein said CPAA is a 16C3 antigen.
A method for diagnosing or treating colorectal or pancreatic carcinoma or associated pathologies and/or promoting tumor regression in a subject, comprising administering to a subject an effective amount of a monoclonal antibody, or an antigen-binding fragment or derivative thereof, that binds colorectal and pancreatic carcinoma-associated antigens (CPAA), wherein said CPAA is a 16C3 antigen.
Dependencies are inferred from the claim text.